Roger Jeffs Sells 22,343 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA - Get Free Report) CEO Roger Jeffs sold 22,343 shares of Liquidia stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the transaction, the chief executive officer now owns 1,019,177 shares of the company's stock, valued at $12,005,905.06. The trade was a 2.15 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Liquidia Price Performance

Shares of LQDA traded down $0.40 during trading hours on Tuesday, hitting $11.36. The stock had a trading volume of 552,977 shares, compared to its average volume of 728,753. Liquidia Co. has a 12 month low of $8.26 and a 12 month high of $16.99. The firm has a market capitalization of $961.48 million, a PE ratio of -6.97 and a beta of 0.23. The stock has a fifty day moving average price of $11.18 and a 200 day moving average price of $11.02.

Institutional Trading of Liquidia

Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Liquidia by 855.3% in the third quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company's stock worth $2,354,000 after acquiring an additional 210,753 shares during the period. Barclays PLC grew its holdings in Liquidia by 265.0% during the third quarter. Barclays PLC now owns 99,984 shares of the company's stock valued at $999,000 after purchasing an additional 72,591 shares during the period. Anson Funds Management LP bought a new stake in Liquidia during the third quarter valued at about $1,764,000. XTX Topco Ltd bought a new stake in Liquidia during the third quarter valued at about $323,000. Finally, Wellington Management Group LLP grew its holdings in Liquidia by 12.5% during the third quarter. Wellington Management Group LLP now owns 179,923 shares of the company's stock valued at $1,799,000 after purchasing an additional 19,932 shares during the period. Institutional investors own 64.54% of the company's stock.

Wall Street Analyst Weigh In

LQDA has been the subject of a number of recent research reports. Scotiabank initiated coverage on Liquidia in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $30.00 price objective for the company. Lifesci Capital initiated coverage on Liquidia in a research note on Thursday, October 3rd. They set an "outperform" rating and a $30.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They set an "overweight" rating and a $20.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday, January 9th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $25.38.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.